Management of Hypertensive Emergency During LSCS

Definition and Assessment

Hypertensive emergency during LSCS is defined as severe blood pressure elevation (typically >180/120 mmHg) with evidence of acute end-organ damage requiring immediate intervention 3, 4
Assessment should focus on identifying signs of end-organ damage including cardiac, neurological, renal, and retinal complications 3, 4, 5

The European Society of Cardiology recommends intravenous labetalol as the first-line treatment for hypertensive emergency during LSCS, with an initial dose of 20 mg IV over 2 minutes, which can be repeated 20-80 mg every 10 minutes up to a total dose of 300 mg 3, 5
The American Heart Association suggests intravenous nicardipine as an effective alternative, with an initial dose of 5 mg/h, increased by 2.5 mg/h every 5 minutes to a maximum of 15 mg/h 1, 2, 3

The European Society of Cardiology recommends a target blood pressure of <160/105 mmHg to prevent acute hypertensive complications in the mother 2
The American Heart Association advises avoiding excessive blood pressure reduction (>25% in the first hour) as it may lead to placental hypoperfusion 3, 5

Continuous maternal blood pressure monitoring is essential during treatment, as recommended by the American Heart Association 3
Fetal heart rate monitoring is mandatory, especially when using labetalol, to detect fetal bradycardia, as suggested by the European Society of Cardiology 2

Consider magnesium sulfate for seizure prophylaxis in cases of severe pre-eclampsia or eclampsia, as recommended by the European Society of Cardiology 2
Timely institution of oral antihypertensive therapy (e.g., methyldopa or long-acting nifedipine) should be considered once BP is stabilized, as suggested by the American Heart Association 2

After initial stabilization, transition to oral antihypertensive medications, as recommended by the European Society of Cardiology 2, 5
Close monitoring should continue for at least 24-48 hours post-delivery, as suggested by the American Heart Association 5

The speed and magnitude of BP reduction should be carefully controlled to prevent maternal hypotension and compromised placental perfusion, as recommended by the European Society of Cardiology 1, 5
If using labetalol, monitor for fetal bradycardia, especially when cumulative dose approaches 800 mg/24h, as suggested by the American Heart Association 2